search
Back to results

Fish Oil (Omega 3 ) in Sjogren's Syndrome

Primary Purpose

Sjogren's Syndrome

Status
Recruiting
Phase
Phase 2
Locations
Iraq
Study Type
Interventional
Intervention
Omega 3 fatty acid
Placebo
Sponsored by
Hawler Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sjogren's Syndrome focused on measuring Sjogren's syndrome, Omega 3 fatty acid, dry eye, dry mouth

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age≥ 18 and ≤ 70 years old .
  • Able to provide inform consent
  • Patients diagnosed as syndrome according to 2016 ACR(American college of Rheumatology)/ EULAR(European league Against Rheumatism classification criteria for Sjögren's syndrome

Exclusion Criteria:

  • any preexisting ocular disease or on eye drops lubricants.
  • patients on (Beta blockers, Diuretics , anticholinergic, α 1antagonist and α 2 agonist ,anticoagulant, antidepressant, antihistamine ,pilocarpine, cevimeline ) .
  • past history of diabetes, psychiatric disorder.
  • pregnancy, lactating mother
  • malignancy

Sites / Locations

  • Reumatology out patient clinic,Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Omega 3 soft gel

placebo

Arm Description

participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.

placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months

Outcomes

Primary Outcome Measures

Dry eye symptoms
subjective symptoms of dry eye which involve 6 symptoms( burning sensation, itching, foreign body sensation , Dryness, mucous discharge, photophobia) when absent(0) , sometime present (1) , frequently present (2), always present (3) ( score 0-6 mild, 6-12 moderate, 12-18 sever by visual analogue scale
Dry mouth symptoms
measure dry mouth by inventory xerostomia score is included 11 questionnaire which score calculated by visual analogue scale from 1 to 5 ( never to very often ) have symptoms

Secondary Outcome Measures

schirmers tear test
patient will sitt in examining chair ,the test strip is bend with round wick and at indentation ( approximately 90 degree ) then patient instruct to look up and draw eye gently downward ,then round bend end of sterile strip hook over eyelid border at junction of middle and outer one third of the lower eyelid margin.
sialometry test
measuring of salivary flow ,unstimulated whole saliva is collect when mouth rinse with distill water then the patient tow his head and try not to move during the test, a plastic disposable pipette drew the accumulated saliva in the floor of the mouth,for a period of five minute,the volume will record ,flow express as ml/min.

Full Information

First Posted
August 5, 2021
Last Updated
April 22, 2022
Sponsor
Hawler Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05005806
Brief Title
Fish Oil (Omega 3 ) in Sjogren's Syndrome
Official Title
Randomised Double-blind Placebo-controlled Clinical Trial of Fish Oil (Omega 3 ) in Sjögren's Syndrome Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 2, 2021 (Actual)
Primary Completion Date
August 2022 (Anticipated)
Study Completion Date
September 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hawler Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Sjögren's syndrome (pSS) is an autoimmune disorder affecting mainly the exocrine glands.this lead to dryness of the main mucosal surface ,such as the mouth ,eye,skin nose,pharynx,larynx and vagina . The history of the disease is characterized by a slowly progression of sicca symptoms and fatigue; however, a subset of patients would experience extra glandular activity. Lipid mediators derived from polyunsaturated fatty acids, related to inflammation and immune response regulation. In this sense, the polyunsaturated fatty acids omega-3 (ω-3 FA) have been associated with several illnesses such as cancer, cardiovascular disease and autoimmune diseases and their balance at the cellular membranes can result in an anti-inflammatory .
Detailed Description
this is a randomized double -blind placebo -controlled clinical trial .the participants will be randomize into two groups .Group 1 receive dietary omega-3 supplementation (omega-3 group) whereas Group 2(placebo group) receive a placebo . The two types are similar to each other in the form of soft gel ,both are given two times daily for two months with follow-up of patients whom they full fill the inclusion criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjogren's Syndrome
Keywords
Sjogren's syndrome, Omega 3 fatty acid, dry eye, dry mouth

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
100 participants will asses for eligibility and underwent randomized double blind placebo controlled clinical trial .in whom they meet inclusion criteria with informed consent from participants and will be held at out patient clinic of Rheumatology department at Erbil- Iraq.
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Omega 3 soft gel
Arm Type
Active Comparator
Arm Description
participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
Intervention Type
Drug
Intervention Name(s)
Omega 3 fatty acid
Intervention Description
omega 3 fatty acid soft gel
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo soft gel
Primary Outcome Measure Information:
Title
Dry eye symptoms
Description
subjective symptoms of dry eye which involve 6 symptoms( burning sensation, itching, foreign body sensation , Dryness, mucous discharge, photophobia) when absent(0) , sometime present (1) , frequently present (2), always present (3) ( score 0-6 mild, 6-12 moderate, 12-18 sever by visual analogue scale
Time Frame
up to two months
Title
Dry mouth symptoms
Description
measure dry mouth by inventory xerostomia score is included 11 questionnaire which score calculated by visual analogue scale from 1 to 5 ( never to very often ) have symptoms
Time Frame
up to two months
Secondary Outcome Measure Information:
Title
schirmers tear test
Description
patient will sitt in examining chair ,the test strip is bend with round wick and at indentation ( approximately 90 degree ) then patient instruct to look up and draw eye gently downward ,then round bend end of sterile strip hook over eyelid border at junction of middle and outer one third of the lower eyelid margin.
Time Frame
up to two months
Title
sialometry test
Description
measuring of salivary flow ,unstimulated whole saliva is collect when mouth rinse with distill water then the patient tow his head and try not to move during the test, a plastic disposable pipette drew the accumulated saliva in the floor of the mouth,for a period of five minute,the volume will record ,flow express as ml/min.
Time Frame
up to two months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age≥ 18 and ≤ 70 years old . Able to provide inform consent Patients diagnosed as syndrome according to 2016 ACR(American college of Rheumatology)/ EULAR(European league Against Rheumatism classification criteria for Sjögren's syndrome Exclusion Criteria: any preexisting ocular disease or on eye drops lubricants. patients on (Beta blockers, Diuretics , anticholinergic, α 1antagonist and α 2 agonist ,anticoagulant, antidepressant, antihistamine ,pilocarpine, cevimeline ) . past history of diabetes, psychiatric disorder. pregnancy, lactating mother malignancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aryan MF Jalal, M.B.CH.B
Phone
009647504880817
Email
aryan.jalal87@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ibtihal HH Faraj, M.B.CH.B
Phone
009647507584463
Email
Ibtihal.hikmet@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ziad SH AL Rawi, F R C P London
Organizational Affiliation
Professor of Rheumatolgy,Baghdad University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Aryan MF Jalal, M.B.CH.B
Organizational Affiliation
Rheumatology,Hawler medical uiversity,Kurdistan Board for medical specialities
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ibtihal HH Faraj, M-B.CH.B
Organizational Affiliation
Rheumatology,Hawler medical university
Official's Role
Principal Investigator
Facility Information:
Facility Name
Reumatology out patient clinic,
City
Erbil
ZIP/Postal Code
44001
Country
Iraq
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Fish Oil (Omega 3 ) in Sjogren's Syndrome

We'll reach out to this number within 24 hrs